Talphera Announces Private Placement Financing of up to $29 Million Priced At-the MarketPRNewsWire • 09/08/25
Wall Street Analysts Think CorMedix (CRMD) Could Surge 32.04%: Read This Before Placing a BetZacks Investment Research • 09/03/25
Is DefenCath Sufficient to Support CorMedix's Long-Term Growth Path?Zacks Investment Research • 09/02/25
CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership TeamGlobeNewsWire • 09/02/25
Wall Street Analysts Believe CorMedix (CRMD) Could Rally 45.63%: Here's is How to TradeZacks Investment Research • 08/18/25
Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry LeadershipBusiness Wire • 08/07/25
CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care SettingsGlobeNewsWire • 08/07/25
Cormedix Inc. Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 08/07/25
CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Q2 ReleaseZacks Investment Research • 08/06/25
Does CorMedix (CRMD) Have the Potential to Rally 65.64% as Wall Street Analysts Expect?Zacks Investment Research • 08/01/25
Concentrix Posts Downbeat Earnings, Joins CorMedix And Other Big Stocks Moving Lower In Friday's Pre-Market SessionBenzinga • 06/27/25
Strength Seen in CorMedix (CRMD): Can Its 21.7% Jump Turn into More Strength?Zacks Investment Research • 06/24/25
CorMedix Spikes To Four-Year High On A Surprise Deal For Its Leading DrugInvestors Business Daily • 06/23/25